Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication October 1, 2019
- Accepted for publication December 17, 2019
- Published online August 3, 2020.
Article Versions
- previous version (January 10, 2020 - 04:59).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Ida Sonni1,
- Matthias Eiber1,2,
- Wolfgang P. Fendler1,3,
- Rejah M. Alano1,
- Sitaram S. Vangala4,
- Amar U. Kishan5–7,
- Nicholas Nickols5–7,
- Matthew B. Rettig6–8,
- Robert E. Reiter6–8,
- Johannes Czernin1,7,8 and
- Jeremie Calais1,7,8
- 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
- 2Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
- 3Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
- 4Department of Medicine Statistics Core, UCLA, Los Angeles, California
- 5Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
- 6Department of Urology, UCLA, Los Angeles, California
- 7Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
- 8Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
- For correspondence or reprints contact: Ida Sonni, David Geffen School of Medicine, UCLA, 200 Medical Plaza, Suite B114, Los Angeles, CA 90095. E-mail: isonni{at}mednet.ucla.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study
- Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
- Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
- Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
- Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
- 177Lu-PSMA Therapy
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
- Assessing the Correlation Between 68Ga-PSMA-11 Renal PET Parameters and Renal Function Tests
- Renal Cortical Scarring: 68Ga-PSMA-11 PET Versus 99mTc-DMSA Scanning in a Case of Pyelonephritis
- Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
- A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics
- Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study
- Renal Cortical 68Ga-PSMA-11 PET and 99mTc-DMSA Images
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy